REG-4basebio Plc: Director/PDMR Shareholding

4BasebioAnnouncement

20/12/2021 12:50

20 December 2021

4basebio plc
(the "Company")
Director’s Dealing

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of cell and gene therapies and
DNA vaccines, announces that, on 17 December 2021 and 20 December 2021, Heikki
Lanckriet, chief executive officer, acquired in aggregate 2,500 ordinary
shares on behalf of his wife at 650 pence per share.

As a result of the acquisition of ordinary shares, Heikki Lanckriet’s
beneficial holding, including shares held by persons closely associated with
him, comprises 1,248,953 ordinary shares representing 10.14 per cent. of the
Company’s issued share capital.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.

For further enquiries, please contact:

 4basebio plc                                        +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                   
                                                                         
 Cairn Financial Advisers LLP (Nominated Adviser )   +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                              
                                                                         
 finnCap Ltd (Broker)                                +44 (0)20 7220 0500 
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe                         
                                                                         

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1. Details of the person discharging managerial responsibilities/person
closely associated
1. Name                      
                                Heikki
Lanckriet
1. Reason for notification
1. Position/Status                    
                Chief Executive Officer
1. Initial notification/ Amendment    Initial
1. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
1. Name
                                                     
4basebio plc
1. LEI
                                                            
213800E2DX9EAIUNCB30
1. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
1. Description of the financial instrument, type Ordinary Shares of instrument

 Identification Code                            
ISIN: GB00BMCLYF79
  
2. Nature of the transaction                 Acquisition of
ordinary shares
  
3. Price(s) and volume(s)       Volume(s)           Price (p)
  
17/12/2021                             1,500
                    650p

20/12/2021                            
1,000                     650p
1. Aggregated information  

 - Aggregated Volume                         2,500
- Price650 pence per share
 
1. Date of the transaction                     17/12/2021
and 20/12/2021
  
2. Place of the transaction London Stock Exchange, AIM


Copyright (c) 2021 PR Newswire Association,LLC. All Rights Reserved